Navigation Links
Study Confirms that OrbusNeich's Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
Date:7/11/2011

ate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedical.


'/>"/>
SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014  Luoxis Diagnostics, Inc., a subsidiary of ... that its academic collaborators will present several peer-reviewed ... its novel RedoxSYS Diagnostic System, a first-in-class platform ... in response to injury or illness.  A poster ... clinical marker will be presented by Christopher ...
(Date:10/20/2014)... -- Valeritas, Inc., a leader in simple, disposable basal-bolus ... diabetes, announced today that it has received a 2014 ... presented October 16 th at Cardinal,s annual Business ... The Cardinal Health Supply Chain Excellence ... specifically targeted at the importance of developing collaborative relationships ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... NEW YORK, March 7, 2011 Reportlinker.com ... is available in its catalogue: ... Future Growth to be Driven by Improving ... http://www.reportlinker.com/p0409144/Aesthetic-Devices-Market-to-2017---Future-Growth-to-be-Driven-by-Improving-Treatment-Outcomes-and-Increase-in-Consumer-Confidence.html ...
... Therapeutics Inc. (TSX: NPC), today announced that their March ... LINK: www.retailinvestorconferences.com Click the red "register/ ... will be available 24/7 for 90 days. Investors may ... the next three weeks. About Allon ...
Cached Medicine Technology:Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 2Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 3Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 3
(Date:10/20/2014)... Myoderm announced today the ... their CentralSource service. Matthew will play ... drug sourcing, distribution, and management service for international ... of industry experience, in both business development and ... their international success to help clients manage their ...
(Date:10/20/2014)... 2014 Final Cut Pro X Plugin developers ... Citrus theme for FCPX filmmakers . , “Fun, cool, ... the Citrus theme” Says Christina Austin, CEO of Pixel Film ... professional.” , Citrus comes with all the tools needed for ... four transitions for added style, a title screen for an ...
(Date:10/20/2014)... 2014 Do you ever feel difficulty ... a wonderful app Metassessor for teachers, specialists and parents. ... helped its client “Intervention Development LLC” to launch Metassessor ... designed for iOS 4.3 or later and is Compatible ... optimized for iPhone 5. It is now available on ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... Charlotte, NC (PRWEB) October 19, 2014 ... muscle building program has just been released to ... throughout the online body building and fitness community. ... the attention of DietsAndFitnessGuides.com's Vin Delmonico prompting an ... the experience of hitting what is commonly known ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... more procedures to reopen arteries, study found , , MONDAY, ... in the left main coronary artery, percutaneous coronary intervention ... be a viable alternative to bypass surgery. , "We ... PCI and surgery," Dr. Seung-Jung Park, senior author of ...
... N.J., March 31 The Palace was the backdrop,for ... Council,(NJTC) crowned the "Best in Show" at the 2008 ... Most Likely to Succeed" and,Switch2Health of New Brunswick took ... event drew a crowd of more than 500 entrepreneurs,and ...
... is available in French . , Montreal, March ... has identified a novel gene responsible for a significant fraction ... referred to as Lou Gehrigs disease, an incurable neuromuscular disorder ... within one to five years. , Published in the current ...
... 2, ,Kick Butts Day, at 11 a.m. in Kettering, ... youth leaders from Ohio will hold a press conference ... describes how tobacco,companies take advantage of the lack of ... products aimed at hooking kids and,preventing current smokers from ...
... New Artis zee Family Provides Interventional Cardiologists with Enhanced ... Imaging for Faster, More Precise Procedures, CHICAGO, ... ranks as America,s No. 1 killer,with an average of one ... the obesity epidemic have contributed to the surge of,Americans with ...
... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) ... independent registered public accounting firm regarding the,Company,s ... the Company,s ability to continue as a ... to publicly announce if,their Annual Report on ...
Cached Medicine News:Health News:Angioplasty Proves Reasonable Alternative to Bypass Surgery 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 3Health News:Researchers identify a gene responsible for Lou Gehrig's disease 2Health News:Ohio Faith Leaders Call on Sen. Voinovich to Cosponsor Legislation to Protect Kids From Tobacco 2Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 2Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 3Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 4Health News:Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K 2Health News:Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K 3
Six inch wide elastic belt transfers the apron weight off the shoulders. 0.5mm front and 0.25mm back with a generous overlap for double protection. Shoulder pads included. Also available without wide...
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... pocket-size peripheral nerve stimulator ... full-function nerve locator or ... depending upon which patient ... Includes NSL-5 electrode lead ...
Low pressure automatic tourniquet with manual time. Includes extension hose and spiral replacement hose....
Medicine Products: